A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
- Registration Number
- NCT06176768
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 75
- Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline
- Have venous access sufficient to allow for blood sampling
- Are able to swallow oral medication
- Agree to skin biopsies
- Have any other skin conditions, excluding plaque psoriasis
- Have a current or recent acute, active infection
- Have manifestations of other autoimmune diseases, such as systemic lupus erythematosus.
- Are lactating or breastfeeding women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LY3972406 Dose 2 LY3972406 Participants will receive an oral dose of LY3972406 Placebo Placebo Participants will receive placebo. LY3972406 Dose 1 LY3972406 Participants will receive an oral dose of LY3972406
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75) Week 12
- Secondary Outcome Measures
Name Time Method Mean Change from Baseline in Body Surface Area (BSA) Baseline, Week 12 Mean Change from Baseline in Dermatology Life Quality Index (DLQI) Baseline, Week 12 Pharmacokinetics (PK): Plasma Concentration of LY3972406 Week 12
Trial Locations
- Locations (12)
Dermatology Research Associates
🇺🇸Los Angeles, California, United States
Clinical Science Institute
🇺🇸Santa Monica, California, United States
Driven Research
🇺🇸Coral Gables, Florida, United States
Conquest Research
🇺🇸Winter Park, Florida, United States
Psoriasis Treatment Center of Central New Jersey
🇺🇸East Windsor, New Jersey, United States
Schweiger Dermatology Group
🇺🇸Hackensack, New Jersey, United States
Metropolitan Dermatology - Clark
🇺🇸Kenilworth, New Jersey, United States
Accellacare - Winston-Salem
🇺🇸Winston-Salem, North Carolina, United States
Remington-Davis, Inc
🇺🇸Columbus, Ohio, United States
DermDox Centers for Dermatology
🇺🇸Camp Hill, Pennsylvania, United States
Center for Clinical Studies
🇺🇸Houston, Texas, United States
Austin Institute for Clinical Research
🇺🇸Houston, Texas, United States